Literature DB >> 2853217

Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection.

F Bistoni1, G Verducci, S Perito, A Vecchiarelli, P Puccetti, P Marconi, A Cassone.   

Abstract

Systemic infection of mice with a Candida albicans strain (PCA-2) incapable of yeast-mycelial conversion is known to activate host macrophages and confer protection against subsequent challenge with highly pathogenic cells of the same species or by other micro-organisms. In an attempt to define the relative contributions of different immune components to the protection mediated by PCA-2, we evaluated the effect of manipulations known to selectively deplete immune functions. By means of cytostatic drug or silica induced toxicity, it was possible to demonstrate that no crucial role in protection is played by cytotoxic T lymphocytes or B cells, nor by PCA-2 induced granulocytosis alone. The cells responsible for this effect were dacarbazine-resistant silica-sensitive macrophages whose activity in vivo paralleled the in vitro expression of splenic candidacidal activity. Macrophage activation by PCA-2 and increased anti-Candida resistance did not result from an immunological response mediated by T-dependent effectors, as these effects could be reproduced in athymic mice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2853217     DOI: 10.1080/02681218880000401

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  37 in total

Review 1.  Immune defence against Candida fungal infections.

Authors:  Mihai G Netea; Leo A B Joosten; Jos W M van der Meer; Bart-Jan Kullberg; Frank L van de Veerdonk
Journal:  Nat Rev Immunol       Date:  2015-09-21       Impact factor: 53.106

Review 2.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

3.  Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes.

Authors:  Johanneke Kleinnijenhuis; Jessica Quintin; Frank Preijers; Leo A B Joosten; Daniela C Ifrim; Sadia Saeed; Cor Jacobs; Joke van Loenhout; Dirk de Jong; Hendrik G Stunnenberg; Ramnik J Xavier; Jos W M van der Meer; Reinout van Crevel; Mihai G Netea
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

4.  Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice.

Authors:  E Cenci; L Romani; A Vecchiarelli; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

5.  An overview of current Italian studies on bacterial pathogenesis.

Authors:  G Falcone
Journal:  World J Microbiol Biotechnol       Date:  1992-12       Impact factor: 3.312

Review 6.  Adaptive features of innate immune cells and their relevance to graft rejection.

Authors:  Guangchuan Wang; Gangcheng Kong; Xian C Li
Journal:  Curr Opin Organ Transplant       Date:  2019-12       Impact factor: 2.640

7.  Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance.

Authors:  L Romani; S Mocci; C Bietta; L Lanfaloni; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

Review 8.  Trained innate immunity: a salient factor in the pathogenesis of neuroimmune psychiatric disorders.

Authors:  A P Salam; A Borsini; P A Zunszain
Journal:  Mol Psychiatry       Date:  2017-12-12       Impact factor: 15.992

9.  Early differential molecular response of a macrophage cell line to yeast and hyphal forms of Candida albicans.

Authors:  E Blasi; L Pitzurra; M Puliti; L Lanfrancone; F Bistoni
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

10.  Acquired immunity in experimental murine aspergillosis is mediated by macrophages.

Authors:  L de Repentigny; S Petitbois; M Boushira; E Michaliszyn; S Sénéchal; N Gendron; S Montplaisir
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.